Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, commonly referred to as Ligand, is a prominent biopharmaceutical company headquartered in the United States. Founded in 1992, Ligand has established itself as a leader in the life sciences industry, focusing on the development of innovative therapies and drug discovery solutions. The company operates primarily in the United States, with significant influence in global markets. Ligand's core business areas include the development of proprietary drug candidates and the licensing of its extensive portfolio of drug discovery technologies. Notable products such as the Captisol® technology, which enhances the solubility and stability of pharmaceutical compounds, set Ligand apart in the competitive landscape. With a strong market position, Ligand has achieved numerous milestones, including strategic partnerships with major pharmaceutical companies, solidifying its reputation as a key player in advancing healthcare solutions.
DitchCarbon Score
How does Ligand Pharmaceuticals Incorporated's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ligand Pharmaceuticals Incorporated's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ligand Pharmaceuticals Incorporated's reported carbon emissions
Ligand Pharmaceuticals Incorporated, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate commitments, including those aligned with the Science Based Targets initiative (SBTi). As a result, Ligand Pharmaceuticals has not established any significant climate initiatives or pledges to reduce their carbon footprint. Without available emissions data or reduction strategies, it is unclear how the company is addressing climate change within its operations. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction; however, Ligand Pharmaceuticals has yet to publicly commit to such initiatives.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ligand Pharmaceuticals Incorporated is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
